Truqap

Overview

capivasertib

kinase inhibitor

• CYP3A4 substrate
• CYP2D6 inhibitor, moderate
• CYP3A4 inhibitor, weak
• UGT1A1 inhibitor
• hyperglycemic effects

Contraindicated

• cisapride
Truqap (capivasertib)

+

cisapride

1 interaction

Contraindicated

capivasertib + cisapride

contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• eliglustat
Truqap (capivasertib)

+

eliglustat

1 interaction

Contraindicated

capivasertib + eliglustat

CYP2D6 EM: contraindicated if Child-Pugh Class A; otherwise, monitor ECG; decr. eliglustat dose to 84 mg qd; CYP2D6 IM: monitor ECG; decr. eliglustat dose to 84 mg qd; CYP2D6 PM: avoid combo: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• thioridazine
Truqap (capivasertib)

+

thioridazine

1 interaction

Contraindicated

capivasertib + thioridazine

contraindicated: combo may incr. thioridazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

Avoid/Use Alternative

• adagrasib
Truqap (capivasertib)

+

adagrasib

1 interaction

Avoid/Use Alternative

capivasertib + adagrasib

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• alprazolam
Truqap (capivasertib)

+

alprazolam

1 interaction

Avoid/Use Alternative

capivasertib + alprazolam

use alternative or monitor respiratory rate, glucose; consider decr. alprazolam dose: combo may incr. levels of both drugs, risk of CNS and respiratory depression, psychomotor impairment, severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• amphetamine
Truqap (capivasertib)

+

amphetamine

1 interaction

Avoid/Use Alternative

capivasertib + amphetamine

consider alternative or monitor serotonin syndrome sx, especially during initiation/titration; decr. amphetamine start dose: combo may incr. amphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metabolism inhibited)

• apalutamide
Truqap (capivasertib)

+

apalutamide

1 interaction

Avoid/Use Alternative

capivasertib + apalutamide

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• atazanavir
Truqap (capivasertib)

+

atazanavir

1 interaction

Avoid/Use Alternative

capivasertib + atazanavir

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• belinostat
Truqap (capivasertib)

+

belinostat

1 interaction

Avoid/Use Alternative

capivasertib + belinostat

use alternative or monitor CBC; decr. belinostat dose as follows: if on belinostat 1000 mg^m2, decr. to 750 mg^m2; if on belinostat 750 mg^m2, decr. to 562.5 mg/m^2; if on belinostat 500 mg/m^2, hold belinostat during capivasertib use: combo may incr. belinostat levels, risk of serious infection, myelosuppression, other adverse effects (UGT inhibited)

• bosentan
Truqap (capivasertib)

+

bosentan

1 interaction

Avoid/Use Alternative

capivasertib + bosentan

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• butalbital
Truqap (capivasertib)

+

butalbital

1 interaction

Avoid/Use Alternative

capivasertib + butalbital

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• carbamazepine
Truqap (capivasertib)

+

carbamazepine

1 interaction

Avoid/Use Alternative

capivasertib + carbamazepine

avoid combo: combo may decr. capivasertib levels, efficacy; may incr. carbamazepine levels, risk of adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

• cenobamate
Truqap (capivasertib)

+

cenobamate

1 interaction

Avoid/Use Alternative

capivasertib + cenobamate

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• ceritinib
Truqap (capivasertib)

+

ceritinib

1 interaction

Avoid/Use Alternative

capivasertib + ceritinib

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• chloramphenicol
Truqap (capivasertib)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

capivasertib + chloramphenicol

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• clarithromycin
Truqap (capivasertib)

+

clarithromycin

1 interaction

Avoid/Use Alternative

capivasertib + clarithromycin

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• cobicistat
Truqap (capivasertib)

+

cobicistat

1 interaction

Avoid/Use Alternative

capivasertib + cobicistat

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• codeine
Truqap (capivasertib)

+

codeine

1 interaction

Avoid/Use Alternative

capivasertib + codeine

use alternative or monitor respiratory rate, withdrawal sx; consider decr. codeine dose: combo may incr. codeine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects; may incr. or decr. active metabolite morphine levels, incr. risk of CNS and respiratory depression, psychomotor impairment, other adverse effects or decr. efficacy (hepatic metabolism inhibited, may incr. or decr. production of active metabolite morphine)

• colchicine
Truqap (capivasertib)

+

colchicine

1 interaction

Avoid/Use Alternative

capivasertib + colchicine

CV RISK REDUCTION: consider monitoring CK, myopathy s/sx; GOUT or FMF: use alternative or consider decr. colchicine dose during and x14 days after capivasertib use: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metabolism inhibited)

• dabrafenib
Truqap (capivasertib)

+

dabrafenib

1 interaction

Avoid/Use Alternative

capivasertib + dabrafenib

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• dextroamphetamine
Truqap (capivasertib)

+

dextroamphetamine

1 interaction

Avoid/Use Alternative

capivasertib + dextroamphetamine

consider alternative or monitor serotonin syndrome sx, especially during initiation/titration; decr. dextroamphetamine start dose: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metabolism inhibited)

• dihydrocodeine
Truqap (capivasertib)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

capivasertib + dihydrocodeine

use alternative or monitor respiratory rate, withdrawal sx: combo may incr. dihydrocodeine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects; may decr. active metabolite dihydromorphine levels, efficacy (hepatic metabolism inhibited, decr. conversion to dihydromorphine)

• doxorubicin
Truqap (capivasertib)

+

doxorubicin

1 interaction

Avoid/Use Alternative

capivasertib + doxorubicin

avoid combo: combo may incr. doxorubicin levels, risk serious infection, myelosuppression, cardiotoxicity, other adverse effects (hepatic metabolism inhibited)

• efavirenz
Truqap (capivasertib)

+

efavirenz

1 interaction

Avoid/Use Alternative

capivasertib + efavirenz

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• encorafenib
Truqap (capivasertib)

+

encorafenib

1 interaction

Avoid/Use Alternative

capivasertib + encorafenib

avoid combo: combo may decr. capivasertib levels, efficacy; may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

• enzalutamide
Truqap (capivasertib)

+

enzalutamide

1 interaction

Avoid/Use Alternative

capivasertib + enzalutamide

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• etravirine
Truqap (capivasertib)

+

etravirine

1 interaction

Avoid/Use Alternative

capivasertib + etravirine

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• fexinidazole
Truqap (capivasertib)

+

fexinidazole

1 interaction

Avoid/Use Alternative

capivasertib + fexinidazole

avoid combo: combo may decr. capivasertib levels, efficacy; may decr. fexinidazole active metabolite levels, efficacy (hepatic metabolism induced; hepatic metabolism inhibited, decr. conversion to active metabolites)

• fosamprenavir
Truqap (capivasertib)

+

fosamprenavir

1 interaction

Avoid/Use Alternative

capivasertib + fosamprenavir

consider alternative: combo may incr. or decr. capivasertib levels, incr. risk of severe hyperglycemia, other adverse effects or decr. efficacy (hepatic metabolism altered)

• fosphenytoin
Truqap (capivasertib)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

capivasertib + fosphenytoin

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• grapefruit
Truqap (capivasertib)

+

grapefruit

1 interaction

Avoid/Use Alternative

capivasertib + grapefruit

avoid combo: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (GI metabolism inhibited)

• hydrocodone
Truqap (capivasertib)

+

hydrocodone

1 interaction

Avoid/Use Alternative

capivasertib + hydrocodone

use alternative or monitor respiratory rate, ECG, consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• idelalisib
Truqap (capivasertib)

+

idelalisib

1 interaction

Avoid/Use Alternative

capivasertib + idelalisib

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• irinotecan
Truqap (capivasertib)

+

irinotecan

1 interaction

Avoid/Use Alternative

capivasertib + irinotecan

use alternative: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (UGT inhibited)

• itraconazole
Truqap (capivasertib)

+

itraconazole

1 interaction

Avoid/Use Alternative

capivasertib + itraconazole

during and x2wk after itraconazole tx, use alternative or monitor glucose and decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• ivosidenib
Truqap (capivasertib)

+

ivosidenib

1 interaction

Avoid/Use Alternative

capivasertib + ivosidenib

avoid combo: combo may decr. capivasertib levels, efficacy; may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

• ketoconazole
Truqap (capivasertib)

+

ketoconazole

1 interaction

Avoid/Use Alternative

capivasertib + ketoconazole

during and up to 1wk after ketoconazole tx, use alternative or monitor glucose and decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• lenacapavir
Truqap (capivasertib)

+

lenacapavir

1 interaction

Avoid/Use Alternative

capivasertib + lenacapavir

avoid combo if also combined w/ strong CYP3A4 and P-gp inhibitors; otherwise, monitor glucose and decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off during and x9mo after lenacapavir tx: combo may incr. level of both drugs, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited, UGT inhibited)

• levoketoconazole
Truqap (capivasertib)

+

levoketoconazole

1 interaction

Avoid/Use Alternative

capivasertib + levoketoconazole

use alternative or monitor glucose, consider monitoring ECG; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• lisdexamfetamine
Truqap (capivasertib)

+

lisdexamfetamine

1 interaction

Avoid/Use Alternative

capivasertib + lisdexamfetamine

use alternative or decr. lisdexamfetamine start dose; monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. dextroamphetamine levels, risk of serotonin syndrome, other adverse effects (hepatic metabolism inhibited)

• lonafarnib
Truqap (capivasertib)

+

lonafarnib

1 interaction

Avoid/Use Alternative

capivasertib + lonafarnib

use alternative or monitor glucose, HR, ECG, electrolytes; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• lopinavir/ritonavir
Truqap (capivasertib)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

capivasertib + lopinavir/ ritonavir

avoid combo: combo may incr. or decr. capivasertib levels, incr. risk of severe hyperglycemia, other adverse effects or decr. efficacy (hepatic metabolism altered)

• lorlatinib
Truqap (capivasertib)

+

lorlatinib

1 interaction

Avoid/Use Alternative

capivasertib + lorlatinib

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• lumacaftor/ivacaftor
Truqap (capivasertib)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

capivasertib + lumacaftor/ ivacaftor

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• mavacamten
Truqap (capivasertib)

+

mavacamten

1 interaction

Avoid/Use Alternative

capivasertib + mavacamten

avoid combo: combo may decr. capivasertib levels, efficacy; may incr. mavacamten levels, risk of heart failure, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

• meperidine
Truqap (capivasertib)

+

meperidine

1 interaction

Avoid/Use Alternative

capivasertib + meperidine

use alternative or monitor respiratory rate, ECG: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• methadone
Truqap (capivasertib)

+

methadone

1 interaction

Avoid/Use Alternative

capivasertib + methadone

use alternative or monitor respiratory rate, ECG, consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• mifepristone
Truqap (capivasertib)

+

mifepristone

1 interaction

Avoid/Use Alternative

capivasertib + mifepristone

during and x14 days after daily mifepristone use, use alternative or monitor glucose and decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• mitapivat
Truqap (capivasertib)

+

mitapivat

1 interaction

Avoid/Use Alternative

capivasertib + mitapivat

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• mitotane
Truqap (capivasertib)

+

mitotane

1 interaction

Avoid/Use Alternative

capivasertib + mitotane

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• modafinil
Truqap (capivasertib)

+

modafinil

1 interaction

Avoid/Use Alternative

capivasertib + modafinil

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• nafcillin
Truqap (capivasertib)

+

nafcillin

1 interaction

Avoid/Use Alternative

capivasertib + nafcillin

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• nefazodone
Truqap (capivasertib)

+

nefazodone

1 interaction

Avoid/Use Alternative

capivasertib + nefazodone

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• nelfinavir
Truqap (capivasertib)

+

nelfinavir

1 interaction

Avoid/Use Alternative

capivasertib + nelfinavir

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• oliceridine
Truqap (capivasertib)

+

oliceridine

1 interaction

Avoid/Use Alternative

capivasertib + oliceridine

use alternative or monitor respiratory rate, ECG; consider decr. oliceridine frequency: combo may incr. oliceridine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• oxycodone
Truqap (capivasertib)

+

oxycodone

1 interaction

Avoid/Use Alternative

capivasertib + oxycodone

use alternative or monitor respiratory rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• pacritinib
Truqap (capivasertib)

+

pacritinib

1 interaction

Avoid/Use Alternative

capivasertib + pacritinib

avoid combo: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (including life-threatening), other adverse effects; may decr. capivasertib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• pentobarbital
Truqap (capivasertib)

+

pentobarbital

1 interaction

Avoid/Use Alternative

capivasertib + pentobarbital

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• pexidartinib
Truqap (capivasertib)

+

pexidartinib

1 interaction

Avoid/Use Alternative

capivasertib + pexidartinib

avoid combo: combo may decr. capivasertib levels, efficacy; may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

• phenobarbital
Truqap (capivasertib)

+

phenobarbital

1 interaction

Avoid/Use Alternative

capivasertib + phenobarbital

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• phenytoin
Truqap (capivasertib)

+

phenytoin

1 interaction

Avoid/Use Alternative

capivasertib + phenytoin

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• pimozide
Truqap (capivasertib)

+

pimozide

1 interaction

Avoid/Use Alternative

capivasertib + pimozide

avoid combo: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• pirfenidone
Truqap (capivasertib)

+

pirfenidone

1 interaction

Avoid/Use Alternative

capivasertib + pirfenidone

avoid combo if also combined w/ mod-strong CYP1A2 inhibitor; otherwise, caution advised: combo may incr. pirfenidone levels, risk of adverse effects (hepatic metabolism inhibited)

• posaconazole
Truqap (capivasertib)

+

posaconazole

1 interaction

Avoid/Use Alternative

capivasertib + posaconazole

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• pralsetinib
Truqap (capivasertib)

+

pralsetinib

1 interaction

Avoid/Use Alternative

capivasertib + pralsetinib

if also combined w/ P-gp inhibitor, use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd; otherwise, consider monitoring ECG, electrolytes: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• primidone
Truqap (capivasertib)

+

primidone

1 interaction

Avoid/Use Alternative

capivasertib + primidone

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• propafenone
Truqap (capivasertib)

+

propafenone

1 interaction

Avoid/Use Alternative

capivasertib + propafenone

avoid combo: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metabolism inhibited)

• repotrectinib
Truqap (capivasertib)

+

repotrectinib

1 interaction

Avoid/Use Alternative

capivasertib + repotrectinib

avoid combo: combo may decr. capivasertib levels, efficacy; may incr. repotrectinib levels, risk of adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

• ribociclib
Truqap (capivasertib)

+

ribociclib

1 interaction

Avoid/Use Alternative

capivasertib + ribociclib

use alternative or monitor glucose, ECG, electrolytes, CBC; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• rifabutin
Truqap (capivasertib)

+

rifabutin

1 interaction

Avoid/Use Alternative

capivasertib + rifabutin

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• rifampin
Truqap (capivasertib)

+

rifampin

1 interaction

Avoid/Use Alternative

capivasertib + rifampin

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• rifapentine
Truqap (capivasertib)

+

rifapentine

1 interaction

Avoid/Use Alternative

capivasertib + rifapentine

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• ritonavir
Truqap (capivasertib)

+

ritonavir

1 interaction

Avoid/Use Alternative

capivasertib + ritonavir

consider alternative: combo may incr. or decr. capivasertib levels, incr. risk of severe hyperglycemia, other adverse effects or decr. efficacy (hepatic metabolism altered)

• sacituzumab govitecan
Truqap (capivasertib)

+

sacituzumab govitecan

1 interaction

Avoid/Use Alternative

capivasertib + sacituzumab govitecan

avoid combo: combo may incr. SN-38 levels, risk of myelosuppression, other adverse effects (UGT inhibited, SN-38 active small molecule moiety of sacituzumab govitecan)

• simvastatin
Truqap (capivasertib)

+

simvastatin

1 interaction

Avoid/Use Alternative

capivasertib + simvastatin

use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 20 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

• sotorasib
Truqap (capivasertib)

+

sotorasib

1 interaction

Avoid/Use Alternative

capivasertib + sotorasib

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• St. John's wort
Truqap (capivasertib)

+

St. John's wort

1 interaction

Avoid/Use Alternative

capivasertib + St. John's wort

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• tamsulosin
Truqap (capivasertib)

+

tamsulosin

1 interaction

Avoid/Use Alternative

capivasertib + tamsulosin

avoid combo if also combined w/ strong CYP3A4 inhibitor; otherwise, monitor BP, especially w/ tamsulosin dose >0.4 mg: combo may incr. tamsulosin levels, risk of hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

• tipranavir
Truqap (capivasertib)

+

tipranavir

1 interaction

Avoid/Use Alternative

capivasertib + tipranavir

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• tramadol
Truqap (capivasertib)

+

tramadol

1 interaction

Avoid/Use Alternative

capivasertib + tramadol

use alternative or monitor respiratory rate, ECG, withdrawal sx: combo may incr. tramadol levels, risk of CNS and respiratory depression, psychomotor impairment, seizures, serotonin syndrome, QT prolongation, cardiac arrhythmias, other adverse effects; may decr. active metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite)

• tucatinib
Truqap (capivasertib)

+

tucatinib

1 interaction

Avoid/Use Alternative

capivasertib + tucatinib

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• voriconazole
Truqap (capivasertib)

+

voriconazole

1 interaction

Avoid/Use Alternative

capivasertib + voriconazole

use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

Monitor/Modify Tx

• abemaciclib
Truqap (capivasertib)

+

abemaciclib

1 interaction

Monitor/Modify Tx

capivasertib + abemaciclib

monitor CBC: combo may incr. abemaciclib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• acalabrutinib
Truqap (capivasertib)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

capivasertib + acalabrutinib

monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• acarbose
Truqap (capivasertib)

+

acarbose

1 interaction

Monitor/Modify Tx

capivasertib + acarbose

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• acetaminophen
Truqap (capivasertib)

+

acetaminophen

1 interaction

Monitor/Modify Tx

capivasertib + acetaminophen

consider acetaminophen dose adjustment: combo may incr. acetaminophen levels, risk of adverse effects (UGT inhibited)

• alfentanil
Truqap (capivasertib)

+

alfentanil

1 interaction

Monitor/Modify Tx

capivasertib + alfentanil

monitor respiratory rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and respiratory depression, psychomotor impairment, delayed recovery from anesthesia, other adverse effects (hepatic metabolism inhibited)

• alogliptin
Truqap (capivasertib)

+

alogliptin

1 interaction

Monitor/Modify Tx

capivasertib + alogliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• amiodarone
Truqap (capivasertib)

+

amiodarone

1 interaction

Monitor/Modify Tx

capivasertib + amiodarone

monitor ECG, glucose: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• amlodipine
Truqap (capivasertib)

+

amlodipine

1 interaction

Monitor/Modify Tx

capivasertib + amlodipine

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• aprepitant
Truqap (capivasertib)

+

aprepitant

1 interaction

Monitor/Modify Tx

capivasertib + aprepitant

if aprepitant 3-day regimen, monitor glucose and decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off; aprepitant single dose-regimen OK: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• aripiprazole oral
Truqap (capivasertib)

+

aripiprazole oral

1 interaction

Monitor/Modify Tx

capivasertib + aripiprazole oral

consider decr. PO aripiprazole dose; if also combined w/ strong CYP3A4 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• asciminib
Truqap (capivasertib)

+

asciminib

1 interaction

Monitor/Modify Tx

capivasertib + asciminib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• atorvastatin
Truqap (capivasertib)

+

atorvastatin

1 interaction

Monitor/Modify Tx

capivasertib + atorvastatin

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• avacopan
Truqap (capivasertib)

+

avacopan

1 interaction

Monitor/Modify Tx

capivasertib + avacopan

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• avanafil
Truqap (capivasertib)

+

avanafil

1 interaction

Monitor/Modify Tx

capivasertib + avanafil

monitor BP; consider decr. avanafil dose: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

• avapritinib
Truqap (capivasertib)

+

avapritinib

1 interaction

Monitor/Modify Tx

capivasertib + avapritinib

monitor bleeding s/sx: combo may incr. avapritinib levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

• belumosudil
Truqap (capivasertib)

+

belumosudil

1 interaction

Monitor/Modify Tx

capivasertib + belumosudil

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• berberine
Truqap (capivasertib)

+

berberine

1 interaction

Monitor/Modify Tx

capivasertib + berberine

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• berotralstat
Truqap (capivasertib)

+

berotralstat

1 interaction

Monitor/Modify Tx

capivasertib + berotralstat

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• bexagliflozin
Truqap (capivasertib)

+

bexagliflozin

1 interaction

Monitor/Modify Tx

capivasertib + bexagliflozin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• bicalutamide
Truqap (capivasertib)

+

bicalutamide

1 interaction

Monitor/Modify Tx

capivasertib + bicalutamide

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• brexpiprazole
Truqap (capivasertib)

+

brexpiprazole

1 interaction

Monitor/Modify Tx

capivasertib + brexpiprazole

if also combined w/ moderate or strong CYP3A4 inhibitor, decr. brexpiprazole dose 75%: combo may incr. brexpiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

• brigatinib
Truqap (capivasertib)

+

brigatinib

1 interaction

Monitor/Modify Tx

capivasertib + brigatinib

monitor BP, HR: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects; may decr. capivasertib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• bromocriptine
Truqap (capivasertib)

+

bromocriptine

1 interaction

Monitor/Modify Tx

capivasertib + bromocriptine

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• canagliflozin
Truqap (capivasertib)

+

canagliflozin

1 interaction

Monitor/Modify Tx

capivasertib + canagliflozin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• chlorzoxazone
Truqap (capivasertib)

+

chlorzoxazone

1 interaction

Monitor/Modify Tx

capivasertib + chlorzoxazone

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• cilostazol
Truqap (capivasertib)

+

cilostazol

1 interaction

Monitor/Modify Tx

capivasertib + cilostazol

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• cimetidine
Truqap (capivasertib)

+

cimetidine

1 interaction

Monitor/Modify Tx

capivasertib + cimetidine

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• ciprofloxacin
Truqap (capivasertib)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

capivasertib + ciprofloxacin

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• clofazimine
Truqap (capivasertib)

+

clofazimine

1 interaction

Monitor/Modify Tx

capivasertib + clofazimine

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• clotrimazole oropharyngeal
Truqap (capivasertib)

+

clotrimazole oropharyngeal

1 interaction

Monitor/Modify Tx

capivasertib + clotrimazole oropharyngeal

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• clozapine
Truqap (capivasertib)

+

clozapine

1 interaction

Monitor/Modify Tx

capivasertib + clozapine

monitor ECG, BP, HR; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, other adverse effects (hepatic metabolism inhibited)

• colesevelam
Truqap (capivasertib)

+

colesevelam

1 interaction

Monitor/Modify Tx

capivasertib + colesevelam

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• conivaptan
Truqap (capivasertib)

+

conivaptan

1 interaction

Monitor/Modify Tx

capivasertib + conivaptan

during and x7 days after conivaptan tx, monitor glucose and decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. level of both drugs, risk of overly rapid serum sodium correction, neurologic sequelae, severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• cranberry
Truqap (capivasertib)

+

cranberry

1 interaction

Monitor/Modify Tx

capivasertib + cranberry

monitor glucose, especially w/ large amounts of cranberry: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (GI metabolism inhibited)

• crizotinib
Truqap (capivasertib)

+

crizotinib

1 interaction

Monitor/Modify Tx

capivasertib + crizotinib

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• cyclosporine
Truqap (capivasertib)

+

cyclosporine

1 interaction

Monitor/Modify Tx

capivasertib + cyclosporine

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• danazol
Truqap (capivasertib)

+

danazol

1 interaction

Monitor/Modify Tx

capivasertib + danazol

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• dapagliflozin
Truqap (capivasertib)

+

dapagliflozin

1 interaction

Monitor/Modify Tx

capivasertib + dapagliflozin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• daridorexant
Truqap (capivasertib)

+

daridorexant

1 interaction

Monitor/Modify Tx

capivasertib + daridorexant

monitor glucose: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• darunavir
Truqap (capivasertib)

+

darunavir

1 interaction

Monitor/Modify Tx

capivasertib + darunavir

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• desipramine
Truqap (capivasertib)

+

desipramine

1 interaction

Monitor/Modify Tx

capivasertib + desipramine

monitor ECG; consider monitoring desipramine levels: combo may incr. desipramine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• deutetrabenazine
Truqap (capivasertib)

+

deutetrabenazine

1 interaction

Monitor/Modify Tx

capivasertib + deutetrabenazine

monitor ECG: combo may incr. deutetrabenazine active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• diltiazem
Truqap (capivasertib)

+

diltiazem

1 interaction

Monitor/Modify Tx

capivasertib + diltiazem

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• diosmin
Truqap (capivasertib)

+

diosmin

1 interaction

Monitor/Modify Tx

capivasertib + diosmin

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• disopyramide
Truqap (capivasertib)

+

disopyramide

1 interaction

Monitor/Modify Tx

capivasertib + disopyramide

monitor disopyramide levels, ECG: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• docetaxel
Truqap (capivasertib)

+

docetaxel

1 interaction

Monitor/Modify Tx

capivasertib + docetaxel

monitor CBC: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• dofetilide
Truqap (capivasertib)

+

dofetilide

1 interaction

Monitor/Modify Tx

capivasertib + dofetilide

monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• domperidone
Truqap (capivasertib)

+

domperidone

1 interaction

Monitor/Modify Tx

capivasertib + domperidone

monitor ECG, HR, electrolytes: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• dronedarone
Truqap (capivasertib)

+

dronedarone

1 interaction

Monitor/Modify Tx

capivasertib + dronedarone

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• dulaglutide
Truqap (capivasertib)

+

dulaglutide

1 interaction

Monitor/Modify Tx

capivasertib + dulaglutide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• duvelisib
Truqap (capivasertib)

+

duvelisib

1 interaction

Monitor/Modify Tx

capivasertib + duvelisib

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• elinzanetant
Truqap (capivasertib)

+

elinzanetant

1 interaction

Monitor/Modify Tx

capivasertib + elinzanetant

monitor glucose: combo may incr. levels of both drugs, risk of severe hyperglycemia, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• empagliflozin
Truqap (capivasertib)

+

empagliflozin

1 interaction

Monitor/Modify Tx

capivasertib + empagliflozin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• entrectinib
Truqap (capivasertib)

+

entrectinib

1 interaction

Monitor/Modify Tx

capivasertib + entrectinib

monitor ECG, CBC, glucose: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• eplerenone
Truqap (capivasertib)

+

eplerenone

1 interaction

Monitor/Modify Tx

capivasertib + eplerenone

monitor potassium: combo may incr. eplerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

• ertugliflozin
Truqap (capivasertib)

+

ertugliflozin

1 interaction

Monitor/Modify Tx

capivasertib + ertugliflozin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• erythromycin
Truqap (capivasertib)

+

erythromycin

1 interaction

Monitor/Modify Tx

capivasertib + erythromycin

monitor ECG, glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• estradiol (contraceptive)
Truqap (capivasertib)

+

estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

capivasertib + estradiol (contraceptive)

monitor thrombosis s/sx: combo may incr. estradiol levels, risk of thromboembolism, other adverse effects (UGT inhibited)

• ethinyl estradiol (contraceptive)
Truqap (capivasertib)

+

ethinyl estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

capivasertib + ethinyl estradiol (contraceptive)

monitor glucose, thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. levels of both drugs, risk of severe hyperglycemia, thromboembolism, other adverse effects (hepatic metabolism inhibited, UGT inhibited)

• everolimus
Truqap (capivasertib)

+

everolimus

1 interaction

Monitor/Modify Tx

capivasertib + everolimus

TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC, glucose; OTHER INDICATIONS: monitor CBC, glucose: combo may incr. levels of both drugs, risk of myelosuppression, severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• exenatide
Truqap (capivasertib)

+

exenatide

1 interaction

Monitor/Modify Tx

capivasertib + exenatide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• fedratinib
Truqap (capivasertib)

+

fedratinib

1 interaction

Monitor/Modify Tx

capivasertib + fedratinib

if fedratinib also combined w/ CYP2C19 inhibitor, monitor CBC, LFTs; otherwise, monitor glucose and decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. levels of both drugs, risk of myelosuppression, hepatotoxicity, severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• felodipine
Truqap (capivasertib)

+

felodipine

1 interaction

Monitor/Modify Tx

capivasertib + felodipine

monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metabolism inhibited)

• fentanyl
Truqap (capivasertib)

+

fentanyl

1 interaction

Monitor/Modify Tx

capivasertib + fentanyl

monitor respiratory rate; consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• finerenone
Truqap (capivasertib)

+

finerenone

1 interaction

Monitor/Modify Tx

capivasertib + finerenone

monitor potassium; if on finerenone 40 mg/day, monitor glucose: combo may incr. levels of both drugs, risk of hyperkalemia, severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• flecainide
Truqap (capivasertib)

+

flecainide

1 interaction

Monitor/Modify Tx

capivasertib + flecainide

monitor flecainide levels, ECG: combo may incr. flecainide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• flibanserin
Truqap (capivasertib)

+

flibanserin

1 interaction

Monitor/Modify Tx

capivasertib + flibanserin

monitor glucose, BP especially if flibanserin also combined w/ other weak CYP3A4 inhibitors: combo may incr. levels of both drugs, risk of CNS depression, psychomotor impairment, severe hypotension (including syncope), severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• fluconazole
Truqap (capivasertib)

+

fluconazole

1 interaction

Monitor/Modify Tx

capivasertib + fluconazole

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• fluvoxamine
Truqap (capivasertib)

+

fluvoxamine

1 interaction

Monitor/Modify Tx

capivasertib + fluvoxamine

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• fosaprepitant
Truqap (capivasertib)

+

fosaprepitant

1 interaction

Monitor/Modify Tx

capivasertib + fosaprepitant

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• fostamatinib
Truqap (capivasertib)

+

fostamatinib

1 interaction

Monitor/Modify Tx

capivasertib + fostamatinib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• gepirone
Truqap (capivasertib)

+

gepirone

1 interaction

Monitor/Modify Tx

capivasertib + gepirone

monitor ECG, electrolytes: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• gepotidacin
Truqap (capivasertib)

+

gepotidacin

1 interaction

Monitor/Modify Tx

capivasertib + gepotidacin

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• ginkgo
Truqap (capivasertib)

+

ginkgo

1 interaction

Monitor/Modify Tx

capivasertib + ginkgo

monitor glucose: combo may incr. or decr. capivasertib levels, incr. risk of severe hyperglycemia, other adverse effects or decr. efficacy (hepatic metabolism altered)

• givinostat
Truqap (capivasertib)

+

givinostat

1 interaction

Monitor/Modify Tx

capivasertib + givinostat

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (GI metabolism inhibited)

• givosiran
Truqap (capivasertib)

+

givosiran

1 interaction

Monitor/Modify Tx

capivasertib + givosiran

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited, givosiran effects on hepatic heme biosynthesis may reduce CYP450 enzyme activity)

• glecaprevir
Truqap (capivasertib)

+

glecaprevir

1 interaction

Monitor/Modify Tx

capivasertib + glecaprevir

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• glimepiride
Truqap (capivasertib)

+

glimepiride

1 interaction

Monitor/Modify Tx

capivasertib + glimepiride

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• glipizide
Truqap (capivasertib)

+

glipizide

1 interaction

Monitor/Modify Tx

capivasertib + glipizide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• glyburide
Truqap (capivasertib)

+

glyburide

1 interaction

Monitor/Modify Tx

capivasertib + glyburide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• goldenseal
Truqap (capivasertib)

+

goldenseal

1 interaction

Monitor/Modify Tx

capivasertib + goldenseal

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• grazoprevir
Truqap (capivasertib)

+

grazoprevir

1 interaction

Monitor/Modify Tx

capivasertib + grazoprevir

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• ibrutinib
Truqap (capivasertib)

+

ibrutinib

1 interaction

Monitor/Modify Tx

capivasertib + ibrutinib

consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• iloperidone
Truqap (capivasertib)

+

iloperidone

1 interaction

Monitor/Modify Tx

capivasertib + iloperidone

monitor ECG: combo may incr. iloperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• imatinib
Truqap (capivasertib)

+

imatinib

1 interaction

Monitor/Modify Tx

capivasertib + imatinib

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• imipramine
Truqap (capivasertib)

+

imipramine

1 interaction

Monitor/Modify Tx

capivasertib + imipramine

monitor imipramine levels: combo may incr. imipramine levels, risk of adverse effects (hepatic metabolism inhibited)

• insulin
Truqap (capivasertib)

+

insulin

1 interaction

Monitor/Modify Tx

capivasertib + insulin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• isavuconazonium
Truqap (capivasertib)

+

isavuconazonium

1 interaction

Monitor/Modify Tx

capivasertib + isavuconazonium

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• isoniazid
Truqap (capivasertib)

+

isoniazid

1 interaction

Monitor/Modify Tx

capivasertib + isoniazid

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• istradefylline
Truqap (capivasertib)

+

istradefylline

1 interaction

Monitor/Modify Tx

capivasertib + istradefylline

monitor glucose, especially w/ istradefylline 40 mg dose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• ivabradine
Truqap (capivasertib)

+

ivabradine

1 interaction

Monitor/Modify Tx

capivasertib + ivabradine

monitor HR, ECG: combo may incr. ivabradine levels, risk of bradycardia, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ivacaftor
Truqap (capivasertib)

+

ivacaftor

1 interaction

Monitor/Modify Tx

capivasertib + ivacaftor

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• ixabepilone
Truqap (capivasertib)

+

ixabepilone

1 interaction

Monitor/Modify Tx

capivasertib + ixabepilone

monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metabolism inhibited)

• kratom
Truqap (capivasertib)

+

kratom

1 interaction

Monitor/Modify Tx

capivasertib + kratom

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• lapatinib
Truqap (capivasertib)

+

lapatinib

1 interaction

Monitor/Modify Tx

capivasertib + lapatinib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• larotrectinib
Truqap (capivasertib)

+

larotrectinib

1 interaction

Monitor/Modify Tx

capivasertib + larotrectinib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• lazertinib
Truqap (capivasertib)

+

lazertinib

1 interaction

Monitor/Modify Tx

capivasertib + lazertinib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• lefamulin
Truqap (capivasertib)

+

lefamulin

1 interaction

Monitor/Modify Tx

capivasertib + lefamulin

ORAL LEFAMULIN: monitor glucose and decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off; IV lefamulin use OK: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• lemborexant
Truqap (capivasertib)

+

lemborexant

1 interaction

Monitor/Modify Tx

capivasertib + lemborexant

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• letermovir
Truqap (capivasertib)

+

letermovir

1 interaction

Monitor/Modify Tx

capivasertib + letermovir

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• linagliptin
Truqap (capivasertib)

+

linagliptin

1 interaction

Monitor/Modify Tx

capivasertib + linagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• liraglutide
Truqap (capivasertib)

+

liraglutide

1 interaction

Monitor/Modify Tx

capivasertib + liraglutide

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• lixisenatide
Truqap (capivasertib)

+

lixisenatide

1 interaction

Monitor/Modify Tx

capivasertib + lixisenatide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• lomitapide
Truqap (capivasertib)

+

lomitapide

1 interaction

Monitor/Modify Tx

capivasertib + lomitapide

ADULT PATIENTS: monitor glucose; if patient on stable capivasertib dose and starting lomitapide, adjust max lomitapide dose to 30 mg/day; if patient on stable lomitapide dose and starting capivasertib, decr. lomitapide dose by 50% and adjust max lomitapide dose to 30 mg/day; PEDIATRIC PATIENTS: monitor glucose; if patient on stable capivasertib dose and starting lomitapide, adjust max lomitapide dose to 10 mg/day if 2-10 yo or 20 mg/day if 11-17 yo; if patient on stable lomitapide dose and starting capivasertib, decr. lomitapide dose by 50% and adjust max lomitapide dose to 10 mg/day if 2-10 yo or 20 mg/day if 11-17 yo: combo may incr. levels of both drugs, risk of severe hyperglycemia, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

• lovastatin
Truqap (capivasertib)

+

lovastatin

1 interaction

Monitor/Modify Tx

capivasertib + lovastatin

monitor glucose, CK, myopathy sx: combo may incr. levels of both drugs, risk of severe hyperglycemia, myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

• lumateperone
Truqap (capivasertib)

+

lumateperone

1 interaction

Monitor/Modify Tx

capivasertib + lumateperone

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• lurasidone
Truqap (capivasertib)

+

lurasidone

1 interaction

Monitor/Modify Tx

capivasertib + lurasidone

monitor ECG, glucose: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• lurbinectedin
Truqap (capivasertib)

+

lurbinectedin

1 interaction

Monitor/Modify Tx

capivasertib + lurbinectedin

monitor CBC: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• maribavir
Truqap (capivasertib)

+

maribavir

1 interaction

Monitor/Modify Tx

capivasertib + maribavir

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• mavorixafor
Truqap (capivasertib)

+

mavorixafor

1 interaction

Monitor/Modify Tx

capivasertib + mavorixafor

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• metformin
Truqap (capivasertib)

+

metformin

1 interaction

Monitor/Modify Tx

capivasertib + metformin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• metoprolol
Truqap (capivasertib)

+

metoprolol

1 interaction

Monitor/Modify Tx

capivasertib + metoprolol

monitor BP, HR; consider lower metoprolol dose: combo may incr. metoprolol levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metabolism inhibited)

• midazolam
Truqap (capivasertib)

+

midazolam

1 interaction

Monitor/Modify Tx

capivasertib + midazolam

monitor respiratory rate: combo may incr. midazolam and active metabolite levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• miglitol
Truqap (capivasertib)

+

miglitol

1 interaction

Monitor/Modify Tx

capivasertib + miglitol

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• milsaperidone
Truqap (capivasertib)

+

milsaperidone

1 interaction

Monitor/Modify Tx

capivasertib + milsaperidone

monitor ECG: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• mobocertinib
Truqap (capivasertib)

+

mobocertinib

1 interaction

Monitor/Modify Tx

capivasertib + mobocertinib

monitor ECG: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. capivasertib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• nateglinide
Truqap (capivasertib)

+

nateglinide

1 interaction

Monitor/Modify Tx

capivasertib + nateglinide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• nebivolol
Truqap (capivasertib)

+

nebivolol

1 interaction

Monitor/Modify Tx

capivasertib + nebivolol

monitor BP, HR: combo may incr. nebivolol levels, risk of hypotension, bradycardia, other adverse effects (hepatic metabolism inhibited)

• netupitant
Truqap (capivasertib)

+

netupitant

1 interaction

Monitor/Modify Tx

capivasertib + netupitant

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off during and x1wk after (fos)netupitant tx: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• nicardipine
Truqap (capivasertib)

+

nicardipine

1 interaction

Monitor/Modify Tx

capivasertib + nicardipine

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• nifedipine
Truqap (capivasertib)

+

nifedipine

1 interaction

Monitor/Modify Tx

capivasertib + nifedipine

monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• nilotinib
Truqap (capivasertib)

+

nilotinib

1 interaction

Monitor/Modify Tx

capivasertib + nilotinib

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• nimodipine
Truqap (capivasertib)

+

nimodipine

1 interaction

Monitor/Modify Tx

capivasertib + nimodipine

monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• nirogacestat
Truqap (capivasertib)

+

nirogacestat

1 interaction

Monitor/Modify Tx

capivasertib + nirogacestat

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• nisoldipine
Truqap (capivasertib)

+

nisoldipine

1 interaction

Monitor/Modify Tx

capivasertib + nisoldipine

monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

• nortriptyline
Truqap (capivasertib)

+

nortriptyline

1 interaction

Monitor/Modify Tx

capivasertib + nortriptyline

monitor nortriptyline levels: combo may incr. nortriptyline levels, risk of adverse effects (hepatic metabolism inhibited)

• osilodrostat
Truqap (capivasertib)

+

osilodrostat

1 interaction

Monitor/Modify Tx

capivasertib + osilodrostat

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• palbociclib
Truqap (capivasertib)

+

palbociclib

1 interaction

Monitor/Modify Tx

capivasertib + palbociclib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• pazopanib
Truqap (capivasertib)

+

pazopanib

1 interaction

Monitor/Modify Tx

capivasertib + pazopanib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• pemigatinib
Truqap (capivasertib)

+

pemigatinib

1 interaction

Monitor/Modify Tx

capivasertib + pemigatinib

monitor phosphate: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

• peppermint
Truqap (capivasertib)

+

peppermint

1 interaction

Monitor/Modify Tx

capivasertib + peppermint

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• perphenazine
Truqap (capivasertib)

+

perphenazine

1 interaction

Monitor/Modify Tx

capivasertib + perphenazine

consider decr. perphenazine dose: combo may incr. perphenazine levels, risk of adverse effects (hepatic metabolism inhibited)

• pibrentasvir
Truqap (capivasertib)

+

pibrentasvir

1 interaction

Monitor/Modify Tx

capivasertib + pibrentasvir

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• pioglitazone
Truqap (capivasertib)

+

pioglitazone

1 interaction

Monitor/Modify Tx

capivasertib + pioglitazone

monitor glucose: combo may decr. capivasertib levels, efficacy; may decr. antidiabetic agent efficacy (hepatic metabolism induced; antagonistic effects)

• pirtobrutinib
Truqap (capivasertib)

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

capivasertib + pirtobrutinib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• pitolisant
Truqap (capivasertib)

+

pitolisant

1 interaction

Monitor/Modify Tx

capivasertib + pitolisant

monitor ECG: combo may incr. pitolisant levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• pramlintide
Truqap (capivasertib)

+

pramlintide

1 interaction

Monitor/Modify Tx

capivasertib + pramlintide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• primaquine
Truqap (capivasertib)

+

primaquine

1 interaction

Monitor/Modify Tx

capivasertib + primaquine

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism possibly inhibited)

• propranolol
Truqap (capivasertib)

+

propranolol

1 interaction

Monitor/Modify Tx

capivasertib + propranolol

monitor BP, HR: combo may incr. propranolol levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metabolism inhibited)

• quercetin
Truqap (capivasertib)

+

quercetin

1 interaction

Monitor/Modify Tx

capivasertib + quercetin

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• quinidine (antiarrhythmic)
Truqap (capivasertib)

+

quinidine (antiarrhythmic)

1 interaction

Monitor/Modify Tx

capivasertib + quinidine (antiarrhythmic)

monitor quinidine levels: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ranolazine
Truqap (capivasertib)

+

ranolazine

1 interaction

Monitor/Modify Tx

capivasertib + ranolazine

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• red yeast rice
Truqap (capivasertib)

+

red yeast rice

1 interaction

Monitor/Modify Tx

capivasertib + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, red yeast rice contains varying amounts of lovastatin)

• remdesivir
Truqap (capivasertib)

+

remdesivir

1 interaction

Monitor/Modify Tx

capivasertib + remdesivir

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• repaglinide
Truqap (capivasertib)

+

repaglinide

1 interaction

Monitor/Modify Tx

capivasertib + repaglinide

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• resveratrol
Truqap (capivasertib)

+

resveratrol

1 interaction

Monitor/Modify Tx

capivasertib + resveratrol

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• rilzabrutinib
Truqap (capivasertib)

+

rilzabrutinib

1 interaction

Monitor/Modify Tx

capivasertib + rilzabrutinib

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. levels of both drugs, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• ritlecitinib
Truqap (capivasertib)

+

ritlecitinib

1 interaction

Monitor/Modify Tx

capivasertib + ritlecitinib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• rosiglitazone
Truqap (capivasertib)

+

rosiglitazone

1 interaction

Monitor/Modify Tx

capivasertib + rosiglitazone

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• rucaparib
Truqap (capivasertib)

+

rucaparib

1 interaction

Monitor/Modify Tx

capivasertib + rucaparib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• saxagliptin
Truqap (capivasertib)

+

saxagliptin

1 interaction

Monitor/Modify Tx

capivasertib + saxagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• selpercatinib
Truqap (capivasertib)

+

selpercatinib

1 interaction

Monitor/Modify Tx

capivasertib + selpercatinib

monitor ECG, electrolytes, glucose: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• semaglutide
Truqap (capivasertib)

+

semaglutide

1 interaction

Monitor/Modify Tx

capivasertib + semaglutide

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• sevabertinib
Truqap (capivasertib)

+

sevabertinib

1 interaction

Monitor/Modify Tx

capivasertib + sevabertinib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• sirolimus
Truqap (capivasertib)

+

sirolimus

1 interaction

Monitor/Modify Tx

capivasertib + sirolimus

monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited)

• sirolimus albumin-bound
Truqap (capivasertib)

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

capivasertib + sirolimus albumin-bound

decr. sirolimus albumin-bound dose to 56 mg/m2; monitor CBC, bleeding s/sx: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

• sitagliptin
Truqap (capivasertib)

+

sitagliptin

1 interaction

Monitor/Modify Tx

capivasertib + sitagliptin

monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• spironolactone
Truqap (capivasertib)

+

spironolactone

1 interaction

Monitor/Modify Tx

capivasertib + spironolactone

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism possibly inhibited)

• stiripentol
Truqap (capivasertib)

+

stiripentol

1 interaction

Monitor/Modify Tx

capivasertib + stiripentol

monitor glucose: combo may incr. or decr. capivasertib levels, incr. risk of severe hyperglycemia, other adverse effects or decr. efficacy (hepatic metabolism altered)

• sufentanil
Truqap (capivasertib)

+

sufentanil

1 interaction

Monitor/Modify Tx

capivasertib + sufentanil

monitor respiratory rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• tacrolimus
Truqap (capivasertib)

+

tacrolimus

1 interaction

Monitor/Modify Tx

capivasertib + tacrolimus

monitor tacrolimus levels, ECG, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

• tadalafil
Truqap (capivasertib)

+

tadalafil

1 interaction

Monitor/Modify Tx

capivasertib + tadalafil

monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

• taletrectinib
Truqap (capivasertib)

+

taletrectinib

1 interaction

Monitor/Modify Tx

capivasertib + taletrectinib

monitor ECG: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• temsirolimus
Truqap (capivasertib)

+

temsirolimus

1 interaction

Monitor/Modify Tx

capivasertib + temsirolimus

monitor CBC: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• tetrabenazine
Truqap (capivasertib)

+

tetrabenazine

1 interaction

Monitor/Modify Tx

capivasertib + tetrabenazine

consider decr. tetrabenazine dose: combo may incr. tetrabenazine active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ticagrelor
Truqap (capivasertib)

+

ticagrelor

1 interaction

Monitor/Modify Tx

capivasertib + ticagrelor

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• tirzepatide
Truqap (capivasertib)

+

tirzepatide

1 interaction

Monitor/Modify Tx

capivasertib + tirzepatide

monitor glucose in type 2 diabetes mellitus pts: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• tolvaptan
Truqap (capivasertib)

+

tolvaptan

1 interaction

Monitor/Modify Tx

capivasertib + tolvaptan

monitor glucose; consider decr. tolvaptan dose: combo may incr. levels of both drugs, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• treosulfan
Truqap (capivasertib)

+

treosulfan

1 interaction

Monitor/Modify Tx

capivasertib + treosulfan

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism possibly inhibited)

• triazolam
Truqap (capivasertib)

+

triazolam

1 interaction

Monitor/Modify Tx

capivasertib + triazolam

monitor respiratory rate; consider decr. triazolam dose: combo may incr. triazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• trofinetide
Truqap (capivasertib)

+

trofinetide

1 interaction

Monitor/Modify Tx

capivasertib + trofinetide

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (GI metabolism inhibited)

• ubrogepant
Truqap (capivasertib)

+

ubrogepant

1 interaction

Monitor/Modify Tx

capivasertib + ubrogepant

limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metabolism inhibited)

• vardenafil
Truqap (capivasertib)

+

vardenafil

1 interaction

Monitor/Modify Tx

capivasertib + vardenafil

monitor ECG: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

• venetoclax
Truqap (capivasertib)

+

venetoclax

1 interaction

Monitor/Modify Tx

capivasertib + venetoclax

monitor CBC, tumor lysis syndrome s/sx: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited)

• verapamil
Truqap (capivasertib)

+

verapamil

1 interaction

Monitor/Modify Tx

capivasertib + verapamil

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. levels of both drugs, risk of hypotension, bradycardia, AV block, severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• viloxazine
Truqap (capivasertib)

+

viloxazine

1 interaction

Monitor/Modify Tx

capivasertib + viloxazine

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• vinblastine
Truqap (capivasertib)

+

vinblastine

1 interaction

Monitor/Modify Tx

capivasertib + vinblastine

monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects; may decr. capivasertib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• vincristine
Truqap (capivasertib)

+

vincristine

1 interaction

Monitor/Modify Tx

capivasertib + vincristine

monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

• vinorelbine
Truqap (capivasertib)

+

vinorelbine

1 interaction

Monitor/Modify Tx

capivasertib + vinorelbine

monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

• vonoprazan
Truqap (capivasertib)

+

vonoprazan

1 interaction

Monitor/Modify Tx

capivasertib + vonoprazan

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• warfarin
Truqap (capivasertib)

+

warfarin

1 interaction

Monitor/Modify Tx

capivasertib + warfarin

monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

• xanomeline
Truqap (capivasertib)

+

xanomeline

1 interaction

Monitor/Modify Tx

capivasertib + xanomeline

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (GI metabolism possibly inhibited)

• yohimbe
Truqap (capivasertib)

+

yohimbe

1 interaction

Monitor/Modify Tx

capivasertib + yohimbe

monitor BP, HR: combo may incr. yohimbe levels, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

• zanubrutinib
Truqap (capivasertib)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

capivasertib + zanubrutinib

monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects; may decr. capivasertib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• ziftomenib
Truqap (capivasertib)

+

ziftomenib

1 interaction

Monitor/Modify Tx

capivasertib + ziftomenib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• zileuton
Truqap (capivasertib)

+

zileuton

1 interaction

Monitor/Modify Tx

capivasertib + zileuton

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

Caution Advised

• armodafinil
Truqap (capivasertib)

+

armodafinil

1 interaction

Caution Advised

capivasertib + armodafinil

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• artemether/lumefantrine
Truqap (capivasertib)

+

artemether/ lumefantrine

1 interaction

Caution Advised

capivasertib + artemether/ lumefantrine

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• belzutifan
Truqap (capivasertib)

+

belzutifan

1 interaction

Caution Advised

capivasertib + belzutifan

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• bexarotene
Truqap (capivasertib)

+

bexarotene

1 interaction

Caution Advised

capivasertib + bexarotene

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• bictegravir
Truqap (capivasertib)

+

bictegravir

1 interaction

Caution Advised

capivasertib + bictegravir

caution advised if also combined w/ CYP3A4 inhibitor: combo may incr. bictegravir levels, risk of adverse effects (UGT inhibited)

• cariprazine
Truqap (capivasertib)

+

cariprazine

1 interaction

Caution Advised

capivasertib + cariprazine

caution advised: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• clobazam
Truqap (capivasertib)

+

clobazam

1 interaction

Caution Advised

capivasertib + clobazam

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• cobimetinib
Truqap (capivasertib)

+

cobimetinib

1 interaction

Caution Advised

capivasertib + cobimetinib

caution advised: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metabolism inhibited)

• cyclophosphamide
Truqap (capivasertib)

+

cyclophosphamide

1 interaction

Caution Advised

capivasertib + cyclophosphamide

caution advised: combo may decr. cyclophosphamide active metabolite levels, efficacy (hepatic metabolism possibly inhibited, decr. conversion to active metabolite)

• danshen
Truqap (capivasertib)

+

danshen

1 interaction

Caution Advised

capivasertib + danshen

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• darolutamide
Truqap (capivasertib)

+

darolutamide

1 interaction

Caution Advised

capivasertib + darolutamide

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• dexamethasone
Truqap (capivasertib)

+

dexamethasone

1 interaction

Caution Advised

capivasertib + dexamethasone

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• dicloxacillin
Truqap (capivasertib)

+

dicloxacillin

1 interaction

Caution Advised

capivasertib + dicloxacillin

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• dihydroergotamine
Truqap (capivasertib)

+

dihydroergotamine

1 interaction

Caution Advised

capivasertib + dihydroergotamine

caution advised: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

• echinacea
Truqap (capivasertib)

+

echinacea

1 interaction

Caution Advised

capivasertib + echinacea

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• elafibranor
Truqap (capivasertib)

+

elafibranor

1 interaction

Caution Advised

capivasertib + elafibranor

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• elagolix
Truqap (capivasertib)

+

elagolix

1 interaction

Caution Advised

capivasertib + elagolix

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• enasidenib
Truqap (capivasertib)

+

enasidenib

1 interaction

Caution Advised

capivasertib + enasidenib

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• ergotamine
Truqap (capivasertib)

+

ergotamine

1 interaction

Caution Advised

capivasertib + ergotamine

caution advised: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

• eslicarbazepine acetate
Truqap (capivasertib)

+

eslicarbazepine acetate

1 interaction

Caution Advised

capivasertib + eslicarbazepine acetate

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• felbamate
Truqap (capivasertib)

+

felbamate

1 interaction

Caution Advised

capivasertib + felbamate

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• garlic
Truqap (capivasertib)

+

garlic

1 interaction

Caution Advised

capivasertib + garlic

caution advised w/ supplemental garlic; dietary intake OK: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• ginseng, Asian
Truqap (capivasertib)

+

ginseng, Asian

1 interaction

Caution Advised

capivasertib + ginseng, Asian

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• glycerol phenylbutyrate
Truqap (capivasertib)

+

glycerol phenylbutyrate

1 interaction

Caution Advised

capivasertib + glycerol phenylbutyrate

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• griseofulvin
Truqap (capivasertib)

+

griseofulvin

1 interaction

Caution Advised

capivasertib + griseofulvin

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• meropenem
Truqap (capivasertib)

+

meropenem

1 interaction

Caution Advised

capivasertib + meropenem

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism possibly induced)

• methylergonovine
Truqap (capivasertib)

+

methylergonovine

1 interaction

Caution Advised

capivasertib + methylergonovine

caution advised: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

• nevirapine
Truqap (capivasertib)

+

nevirapine

1 interaction

Caution Advised

capivasertib + nevirapine

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• odevixibat
Truqap (capivasertib)

+

odevixibat

1 interaction

Caution Advised

capivasertib + odevixibat

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• olutasidenib
Truqap (capivasertib)

+

olutasidenib

1 interaction

Caution Advised

capivasertib + olutasidenib

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism possibly induced)

• omaveloxolone
Truqap (capivasertib)

+

omaveloxolone

1 interaction

Caution Advised

capivasertib + omaveloxolone

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• oxcarbazepine
Truqap (capivasertib)

+

oxcarbazepine

1 interaction

Caution Advised

capivasertib + oxcarbazepine

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• palovarotene
Truqap (capivasertib)

+

palovarotene

1 interaction

Caution Advised

capivasertib + palovarotene

caution advised: combo may incr. palovarotene levels, risk of adverse effects (hepatic metabolism inhibited)

• perampanel
Truqap (capivasertib)

+

perampanel

1 interaction

Caution Advised

capivasertib + perampanel

caution advised if on perampanel 12 mg/day: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• prednisone
Truqap (capivasertib)

+

prednisone

1 interaction

Caution Advised

capivasertib + prednisone

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• roflumilast
Truqap (capivasertib)

+

roflumilast

1 interaction

Caution Advised

capivasertib + roflumilast

caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

• roflumilast topical
Truqap (capivasertib)

+

roflumilast topical

1 interaction

Caution Advised

capivasertib + roflumilast topical

caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

• rufinamide
Truqap (capivasertib)

+

rufinamide

1 interaction

Caution Advised

capivasertib + rufinamide

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• sarilumab
Truqap (capivasertib)

+

sarilumab

1 interaction

Caution Advised

capivasertib + sarilumab

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C)

• sirolimus topical
Truqap (capivasertib)

+

sirolimus topical

1 interaction

Caution Advised

capivasertib + sirolimus topical

caution advised: combo may incr. sirolimus levels, risk of adverse effects (hepatic metabolism inhibited)

• sunvozertinib
Truqap (capivasertib)

+

sunvozertinib

1 interaction

Caution Advised

capivasertib + sunvozertinib

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• suzetrigine
Truqap (capivasertib)

+

suzetrigine

1 interaction

Caution Advised

capivasertib + suzetrigine

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• tamoxifen
Truqap (capivasertib)

+

tamoxifen

1 interaction

Caution Advised

capivasertib + tamoxifen

caution advised: combo may decr. active tamoxifen metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite)

• tazemetostat
Truqap (capivasertib)

+

tazemetostat

1 interaction

Caution Advised

capivasertib + tazemetostat

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• tecovirimat
Truqap (capivasertib)

+

tecovirimat

1 interaction

Caution Advised

capivasertib + tecovirimat

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• telotristat ethyl
Truqap (capivasertib)

+

telotristat ethyl

1 interaction

Caution Advised

capivasertib + telotristat ethyl

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• tocilizumab
Truqap (capivasertib)

+

tocilizumab

1 interaction

Caution Advised

capivasertib + tocilizumab

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes)

• topiramate
Truqap (capivasertib)

+

topiramate

1 interaction

Caution Advised

capivasertib + topiramate

caution advised, especially w/ topiramate doses >200 mg/day: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• tovorafenib
Truqap (capivasertib)

+

tovorafenib

1 interaction

Caution Advised

capivasertib + tovorafenib

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• vaborbactam
Truqap (capivasertib)

+

vaborbactam

1 interaction

Caution Advised

capivasertib + vaborbactam

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism possibly induced)

• vamorolone
Truqap (capivasertib)

+

vamorolone

1 interaction

Caution Advised

capivasertib + vamorolone

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism possibly induced)

• vemurafenib
Truqap (capivasertib)

+

vemurafenib

1 interaction

Caution Advised

capivasertib + vemurafenib

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• vorasidenib
Truqap (capivasertib)

+

vorasidenib

1 interaction

Caution Advised

capivasertib + vorasidenib

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism possibly induced)

• vortioxetine
Truqap (capivasertib)

+

vortioxetine

1 interaction

Caution Advised

capivasertib + vortioxetine

caution advised: combo may incr. vortioxetine levels, risk of adverse effects (hepatic metabolism inhibited)